ANI Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 weeks.
- Its last 6 Sell calls were actually followed by a +10% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -12.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation B+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 13.6x | Better than 63% |
| Forward P/E | 14.1x | Better than 59% |
| Price / Sales | 1.6x | Better than 65% |
| P/E vs own 5-yr range | 60th pctl | Better than 49% |
Growth A
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 40.8% | Better than 94% |
| Net income CAGR (3Y) | 15.7% | Better than 67% |
Profitability B
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 61.4% | Better than 76% |
| Operating margin | 9.2% | Better than 49% |
| Net margin | 7.9% | Better than 53% |
| Return on equity | 14.9% | Better than 68% |
| Return on invested capital | 7.9% | Better than 60% |
Momentum C+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -9.0% | Better than 53% |
| 6-month return | -17.1% | Better than 30% |
| 12-month return (ex latest month) | -8.9% | Better than 24% |
| Distance below 52-week high | 21.9% | Better than 56% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.7x | Better than 69% |
| Debt to assets | 42.8% | Better than 23% |
| Interest coverage | 5.8x | Better than 60% |
| Free cash flow / net income | 192.6% | Better than 75% |
Analyst View B
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 71.4% | Better than 49% |
| Upside to average target | 53.4% | Better than 68% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 69.13
- Open
- 68.96
- Day range
- 68.28 - 70.20
- Avg price
- 68.72
- Volume
- 227.26K
- Turnover
- 15.62M
- Turnover ratei
- 1.08%
- Volume ratioi
- 0.55
- Amplitudei
- 2.78%
- 52-week rangei
- 67.14 - 87.76
Valuation
- P/Ei
- 20.65
- P/E (TTM)i
- 13.63
- P/Bi
- 2.44
- EPSi
- 3.32
- Book value / shi
- 28.04
- Net profit
- 75.43M
- Net assets
- 637.11M
Share structure
- Market cap
- 1.56B
- Float capi
- 1.44B
- Shares out
- 22.72M
- Float sharesi
- 20.96M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
21.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-2.22M net over the window
Short interest
- Shares short
- 3.58M
- % of floati
- 15.61%
- Days to coveri
- 11.88
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of ANI Pharmaceuticals (ANIP)?
ANI Pharmaceuticals last traded at 68.55. This page shows a periodic quote snapshot. Check the displayed quote time.
What is ANI Pharmaceuticals's market cap?
About 1.56B.
What is the P/E ratio of ANI Pharmaceuticals?
The trailing twelve-month P/E is 13.63. The Valuation tab shows it against the stock's own five-year range.
Does ANI Pharmaceuticals pay a dividend?
ANI Pharmaceuticals does not currently pay a regular dividend.
Is ANI Pharmaceuticals a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 105.14, which implies 53.4% upside from the current price. This is not investment advice.
What is ANI Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates ANI Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:01:05 · For reference only, not investment advice and not tailored to your situation.
ANI Pharmaceuticals discussion 0 comments